Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR
Launched by ZAGAZIG UNIVERSITY · Sep 1, 2018
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • chronic HCV
- • compensated liver disease (Child class A-B)
- • sustained virological response
- • liver stiffness by fibroscan \>12.5 kPa denotes cirrhosis
- Exclusion Criteria:
- • decompensated liver disease
- • chronic active HCV
- • hepatocellular carcinoma
- • other liver diseases as alcoholic liver disease, autoimmune liver disease, drug-induced liver disease
- • pregnancy
About Zagazig University
Zagazig University, a prominent educational and research institution located in Egypt, plays a pivotal role in advancing medical knowledge and promoting health innovations through its clinical trials. With a commitment to excellence in research, the university leverages its diverse expertise and state-of-the-art facilities to conduct rigorous clinical studies that aim to improve patient care and outcomes. By fostering collaboration among multidisciplinary teams, Zagazig University contributes significantly to the global medical community, ensuring that its clinical trials adhere to the highest ethical standards and regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials